FirstRanker Logo

FirstRanker.com - FirstRanker's Choice is a hub of Question Papers & Study Materials for B-Tech, B.E, M-Tech, MCA, M.Sc, MBBS, BDS, MBA, B.Sc, Degree, B.Sc Nursing, B-Pharmacy, D-Pharmacy, MD, Medical, Dental, Engineering students. All services of FirstRanker.com are FREE

📱

Get the MBBS Question Bank Android App

Access previous years' papers, solved question papers, notes, and more on the go!

Install From Play Store

Download DNB 2020 June Medical Oncology Paper II Question Paper

Download Diplomate of National Board (DNB) 2020 June Medical Oncology Paper II Question Paper

This post was last modified on 31 July 2021

FINAL EXAM
NATIONAL BOARD OF EXAMINATIONS
JUNE 2020
MEDICAL ONCOLOGY
PAPER-II

--- Content provided by‌ FirstRanker.com ---

Time: 3 hours
MED.ONCO./J/20/17/II
Max. Marks:100
Important Instructions:
Attempt al questions in order.

--- Content provided by‌ FirstRanker.com ---

Each question carries 10 marks.
Read the question careful y and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer all the parts of a single question together.

--- Content provided by FirstRanker.com ---

Start the answer to a question on a fresh page or leave adequate space between two answers.
Draw table/diagrams/flowcharts wherever appropriate.
Write short notes on:
1. a) Define various phases of chronic myeloid leukemia.
3+4+3

--- Content provided by FirstRanker.com ---

b) Selection of first line TKI.
c) When is it safe to stop treatment?
2. a) Classify plasma cell neoplasms.
2+4+4
b) Outline the diagnostic tests for myeloma.

--- Content provided by‍ FirstRanker.com ---

c) Your approach to treatment of multiple myeloma, relapsed after an
Autologous Stem Cell Transplantation.
3. a) Evaluation of a patient presenting with solitary pulmonary nodule.
3
+

--- Content provided by‍ FirstRanker.com ---

3+4
b) Mention the Immunohistochemistry panel to establish tissue diagnosis.
c) Algorithm for treatment of this case.
4. a) Describe management of CINV.
4+3+3

--- Content provided by FirstRanker.com ---

b) What are drugs with ultra-low risk emetogenesis?
c) Side effects of anti-emetic drugs.
5. a) Chemotherapy regimens in Ewing's sarcoma.
3+4+3
b) EURAMOS Trial in Osteosarcoma.

--- Content provided by​ FirstRanker.com ---

c) Histology directed therapies in soft tissue sarcoma.
6. a) Diagnostic workup of obstructive jaundice due to extrinsic compression
3+4+3
of distal biliary tract.
b) Algorithm for treatment of cancer of the head of pancreas.

--- Content provided by​ FirstRanker.com ---

c) Management of pain in a case of carcinoma of pancreas.
7. a) Pathophysiology of hormone resistance in prostate cancer.
3+4+3
b) Algorithm for management of castration resistant prostate cancer.
c) Gynecomastia in a patient of prostate cancer.

--- Content provided by FirstRanker.com ---

8. a) Tumour Lysis Syndrome. (TLS).
2+4+4
b) Risk stratification of TLS.
c) Prevention and management of TLS.
P.T.O

--- Content provided by FirstRanker.com ---

-1-
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.

FINAL EXAM
NATIONAL BOARD OF EXAMINATIONS

--- Content provided by FirstRanker.com ---

JUNE 2020
MEDICAL ONCOLOGY
PAPER-II
9. a) Molecular Classification of Triple Negative Breast Cancer (TNBC). 3+4+3
b) Treatment of TNBC.

--- Content provided by FirstRanker.com ---

c) Counsel ing a patient of TNBC.
10. a) Hyperviscosity syndromes.
3+4+3
b) Extravasation of various chemotherapeutic agents and their
management.

--- Content provided by​ FirstRanker.com ---

c) Testicular cancer survivorship.
************
-2-
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.

--- Content provided by⁠ FirstRanker.com ---